{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:21:43Z","timestamp":1786980103848,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03137-3","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T12:01:27Z","timestamp":1717675287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Role of IL-23 inhibitors including risankizumab and guselkumab in the treatment of pityriasis rubra pilaris"],"prefix":"10.1007","volume":"316","author":[{"given":"Syed Minhaj","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"3137_CR1","unstructured":"Brown F, Badri T. 2023 Pityriasis rubra pilaris. In: StatPearls. StatPearls Publishing. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482436\/. Accessed 21 June 2023"},{"issue":"7","key":"3137_CR2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1600-0560.1997.tb00816.x","volume":"24","author":"CM Magro","year":"1997","unstructured":"Magro CM, Crowson AN (1997) The clinical and histomorphological features of pityriasis rubra pilaris: a comparative analysis with psoriasis. J Cutan Pathol 24(7):416\u2013424. https:\/\/doi.org\/10.1111\/j.1600-0560.1997.tb00816.x","journal-title":"J Cutan Pathol"},{"issue":"5","key":"3137_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1684\/ejd.2019.3641","volume":"29","author":"C Engelmann","year":"2019","unstructured":"Engelmann C, Elsner P, Miguel D (2019) Treatment of pityriasis rubra pilaris type I: a systematic review. Eur J Dermatol 29(5):524\u2013537. https:\/\/doi.org\/10.1684\/ejd.2019.3641","journal-title":"Eur J Dermatol"},{"issue":"1","key":"3137_CR4","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.jaad.2006.07.019","volume":"56","author":"JE Graves","year":"2007","unstructured":"Graves JE, Nunley K, Heffernan MP (2007) Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2). J Am Acad Dermatol 56(1):e55\u2013e79. https:\/\/doi.org\/10.1016\/j.jaad.2006.07.019","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3137_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/jamadermatol.2020.0932","volume":"156","author":"D Haynes","year":"2020","unstructured":"Haynes D, Strunck JL, Topham CA et al (2020) Evaluation of ixekizumab treatment for patients with pityriasis rubra pilaris: a single-arm trial. JAMA Dermatol 156(6):668. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0932","journal-title":"JAMA Dermatol"},{"key":"3137_CR6","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2147\/CCID.S364640","volume":"15","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M (2022) Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence. CCID 15:1649\u20131658. https:\/\/doi.org\/10.2147\/CCID.S364640","journal-title":"CCID"},{"key":"3137_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"3137_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15112","author":"R Balestri","year":"2021","unstructured":"Balestri R, Magnano M, Girardelli CR, Rech G (2021) Is risankizumab effective in the treatment of pityriasis rubra pilaris? Dermatol Ther. https:\/\/doi.org\/10.1111\/dth.15112","journal-title":"Dermatol Ther"},{"issue":"1","key":"3137_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bjd.20061","volume":"185","author":"B Duarte","year":"2021","unstructured":"Duarte B, Paiva Lopes MJ (2021) Response to: \u2018Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab.\u2019 Br J Dermatol 185(1):235\u2013236. https:\/\/doi.org\/10.1111\/bjd.20061","journal-title":"Br J Dermatol"},{"issue":"7","key":"3137_CR10","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/ced.14715","volume":"46","author":"E Brocco","year":"2021","unstructured":"Brocco E, Laffitte E (2021) Risankizumab for pityriasis rubra pilaris. Clin Exp Dermatol 46(7):1322\u20131324. https:\/\/doi.org\/10.1111\/ced.14715","journal-title":"Clin Exp Dermatol"},{"key":"3137_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18516","author":"A Fouarge","year":"2023","unstructured":"Fouarge A, Cuvelier M, Roquet-Gravy C, De Montjoye L, Baeck M (2023) Successful treatment of pityriasis rubra pilaris with risankizumab, a IL-23\/p19 antagonist. Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.18516","journal-title":"Acad Dermatol Venereol"},{"key":"3137_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19681","author":"J Ricar","year":"2021","unstructured":"Ricar J, Cetkovska P (2021) Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.19681","journal-title":"Br J Dermatol"},{"issue":"8","key":"3137_CR13","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/ddg.14504","volume":"19","author":"C Kromer","year":"2021","unstructured":"Kromer C, Sch\u00f6n MP, M\u00f6ssner R (2021) Treatment of pityriasis rubra pilaris with risankizumab in two cases. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 19(8):1207\u20131209. https:\/\/doi.org\/10.1111\/ddg.14504","journal-title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft."},{"issue":"4","key":"3137_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/ajd.13925","volume":"63","author":"JP Pham","year":"2022","unstructured":"Pham JP, Allen N, Smith A (2022) Efficacy of ustekinumab and guselkumab in treatment refractory pityriasis rubra pilaris: a case series. Aust J Dermatology 63(4):522\u2013524. https:\/\/doi.org\/10.1111\/ajd.13925","journal-title":"Aust J Dermatology"},{"key":"3137_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14403","author":"H Nagai","year":"2020","unstructured":"Nagai H, Jimbo H, Matsuura S, Tatsuoka S, Shiraki E, Nishigori C (2020) Successful treatment of pityriasis rubra pilaris with guselkumab: Serum CCL20 as a potential marker for the disease activity. Dermatol Ther. https:\/\/doi.org\/10.1111\/dth.14403","journal-title":"Dermatol Ther"},{"key":"3137_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.6413","author":"M Nishimura","year":"2022","unstructured":"Nishimura M, Kondo M, Habe K, Hayashi A, Yamanaka K (2022) Successful treatment with cyclosporine and guselkumab for pityriasis rubra pilaris. Clin Case Rep. https:\/\/doi.org\/10.1002\/ccr3.6413","journal-title":"Clin Case Rep"},{"issue":"12","key":"3137_CR17","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1001\/jamadermatol.2019.2774","volume":"155","author":"AC Pilz","year":"2019","unstructured":"Pilz AC, Seiringer P, Biedermann T, Eyerich K (2019) Treatment of pityriasis rubra pilaris with guselkumab. JAMA Dermatol 155(12):1424. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2774","journal-title":"JAMA Dermatol"},{"issue":"4","key":"3137_CR18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/jamadermatol.2016.5384","volume":"153","author":"L Feldmeyer","year":"2017","unstructured":"Feldmeyer L, Mylonas A, Demaria O et al (2017) Interleukin 23\u2013helper T cell 17 axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol 153(4):304. https:\/\/doi.org\/10.1001\/jamadermatol.2016.5384","journal-title":"JAMA Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03137-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03137-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03137-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T07:44:47Z","timestamp":1719387887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03137-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3137"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03137-3","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"assertion":[{"value":"28 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}],"article-number":"334"}}